Drug Discovery · Cambridge, MA · Founded 2024 · Privately Held (backing)
Operator of a biotechnology company intended to develop innovative, precise, and effective treatments for a wide range of diseases. City Therapeutics is based in Cambridge, MA and was founded in 2024. It is valued at about $285 million as of Oct 2026, set by institutional fund marks. It has raised $140 million across 1 recorded round; the latest was a $135 million Series A in Oct 2024.
PMV mark · valuation
$285.5M
Oct 2026
Priced at
its Series A
Oct 2024
Total raised
$139.5M
Last round
Early Stage VC (Series A)
Oct 2024
No prints on record
No secondary trades in City Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of City Therapeutics stock.
